Selected article for: "dysfunction syndrome and rapidly progress"
Author: Zhang, Yue; Xu, Qianhao; Sun, Zhuoyan; Zhou, Lei
Title: Current targeted therapeutics against COVID-19: based on first-line experience in china
  • Cord-id: ahlgybbc
  • Document date: 2020_4_30
    • ID: ahlgybbc
    Snippet: SARS-CoV-2 is a novel strain, causing a global pandemic since the end of 2019. The majority of patients showed nonspecific symptoms such as fever, dry cough, and fatigue. Most patients have a good prognosis while some with severe conditions could rapidly progress to acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation dysfunction, and even die. The exacerbation of the patient's condition may be due to a cytokine storm in the body. Effective targeted therapies includ
    Document: SARS-CoV-2 is a novel strain, causing a global pandemic since the end of 2019. The majority of patients showed nonspecific symptoms such as fever, dry cough, and fatigue. Most patients have a good prognosis while some with severe conditions could rapidly progress to acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation dysfunction, and even die. The exacerbation of the patient's condition may be due to a cytokine storm in the body. Effective targeted therapies including antiviral and immunization are urgently needed. Although many clinical trials are already underway and the majority of patients have received antiviral therapy based on medication experience with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and preliminary results from some clinical trials, there are no antiviral drugs proven to be effective currently. We summarize the current therapeutic medicines used in the clinic, hope to be able to provide some implications for clinical medication.

    Search related documents:
    Co phrase search for related documents
    • active infection and addition time: 1, 2, 3
    • active infection and loading dose: 1, 2
    • active infection and lopinavir ritonavir: 1, 2
    • active infection and low micromolar: 1
    • active infection and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • active infection and lung inflammation: 1, 2, 3, 4, 5
    • active infection and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active infection and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active infection and lung titer: 1
    • activity inhibit and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53
    • activity inhibit and addition time: 1, 2, 3
    • activity inhibit and addition time assay: 1
    • activity inhibit and lopinavir ritonavir: 1, 2
    • activity inhibit and low medium: 1
    • activity inhibit and low micromolar: 1, 2, 3
    • activity inhibit and lung infection: 1, 2
    • activity inhibit and lung inflammation: 1, 2, 3, 4, 5, 6
    • activity inhibit and lung injury: 1, 2, 3, 4, 5, 6
    • activity inhibit and lung tissue: 1, 2, 3, 4